ARYC: AI 评分 58/100 — AI 分析 (4月 2026)

Arrayit Corporation develops and markets life science tools and integrated systems for genetic analysis and diagnostics. The company offers microarray technology, automated instruments, and consumables to research centers and pharmaceutical companies.

Key Facts: AI Score: 58/100 Sector: Healthcare

公司概况

概要：

Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.

ARYC是做什么的？

Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.

ARYC的投资论点是什么？

Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of $0.00B and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.

ARYC在哪个行业运营？

Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.

Medical - Diagnostics & Research

Healthcare

ARYC有哪些增长机遇？

Expanding Microarray Applications in Early Disease Detection: Arrayit can capitalize on the growing demand for early disease detection by developing and marketing diagnostic microarrays for various treatable disease states. The market for early disease diagnostics is projected to reach billions of dollars by 2030, driven by advancements in genomics and proteomics. Arrayit's microarray technology offers a platform for high-throughput screening and personalized medicine, providing a competitive advantage in this expanding market. Timeline: Ongoing.
Increasing Sales of Automated Microarray Instruments: Arrayit can increase revenue by expanding the sales of its automated microarray manufacturing instruments, such as NanoPrint and SpotBot Titan, to research institutions and pharmaceutical companies. The market for automated laboratory equipment is expected to grow, driven by the need for increased efficiency and throughput in research and development. Arrayit's instruments offer customizable solutions for microarray manufacturing, catering to the specific needs of its customers. Timeline: Ongoing.
Developing and Marketing Consumables for Microarray Technology: Arrayit can leverage its existing customer base by developing and marketing consumables, such as glass substrates, reagents, and clean room supplies, for microarray technology. The market for laboratory consumables is stable and recurring, providing a consistent revenue stream for the company. By offering high-quality consumables specifically designed for its instruments, Arrayit can enhance customer loyalty and increase market share. Timeline: Ongoing.
Entering Strategic Partnerships with Pharmaceutical Companies: Arrayit can accelerate its growth by entering strategic partnerships with pharmaceutical companies to develop and commercialize diagnostic microarrays and tools for specific disease areas. Collaborating with established pharmaceutical companies can provide access to funding, expertise, and distribution channels, enabling Arrayit to expand its market reach and product portfolio. These partnerships can focus on developing personalized medicine solutions and companion diagnostics. Timeline: Ongoing.
Expanding into International Markets: Arrayit can expand its geographic reach by targeting international markets, particularly in Asia and Europe, where there is growing demand for life science tools and diagnostic technologies. Entering new markets requires adapting products and services to local regulatory requirements and customer needs. By establishing partnerships with local distributors and research institutions, Arrayit can effectively penetrate these markets and increase its global presence. Timeline: Ongoing.

Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
Market capitalization of $0.00B indicates the company is a micro-cap stock with associated volatility and liquidity risks.
Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.

ARYC提供哪些产品和服务？

Develops microarray tools and components.
Manufactures life science tools and integrated systems.
Markets life science tools and integrated systems.
Offers custom printing and analysis of microarrays for research.
Identifies and develops diagnostic microarrays for early disease detection.
Provides automated microarray manufacturing instruments.

ARYC如何赚钱？

Sales of microarray tools and components to research institutions and pharmaceutical companies.
Custom printing and analysis of microarrays for research purposes.
Development and sales of diagnostic microarrays for early disease detection.
Manufacturing and sales of automated microarray manufacturing instruments.

Genomic research centers
Pharmaceutical companies
Academic institutions
Clinical research organizations
Government agencies
Biotechnology companies

Proprietary microarray printing technology.
Integrated systems for genetic variation analysis.
Established relationships with research institutions and pharmaceutical companies.
Specialized expertise in microarray technology and applications.

什么因素可能推动ARYC股价上涨？

Ongoing: Expansion of microarray applications in early disease detection.
Ongoing: Increasing sales of automated microarray instruments.
Ongoing: Development and marketing of consumables for microarray technology.
Ongoing: Entering strategic partnerships with pharmaceutical companies.
Ongoing: Expanding into international markets.

ARYC的主要风险是什么？

Potential: Competition from larger companies with greater resources.
Potential: Regulatory changes affecting the medical diagnostics industry.
Potential: Technological advancements rendering current products obsolete.
Potential: Economic downturns impacting research funding.
Ongoing: Negative profit margin and limited financial resources.

ARYC的核心优势是什么？

Proprietary microarray printing technology
Integrated systems for genetic variation analysis
Established relationships with research institutions
Specialized expertise in microarray applications

ARYC的劣势是什么？

Negative profit margin
Small market capitalization
High beta indicating high volatility
Limited financial resources

ARYC有哪些机遇？

Expanding microarray applications in early disease detection
Increasing sales of automated microarray instruments
Developing and marketing consumables
Entering strategic partnerships with pharmaceutical companies

ARYC面临哪些威胁？

Competition from larger companies
Regulatory changes
Technological advancements
Economic downturns

Key Metrics

MoonshotScore: 58/100

Company Profile

CEO: Rene A. Schena
Headquarters: Sunnyvale, US
Employees: 7
Founded: 2001

AI Insight

AI analysis pending for ARYC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Arrayit Corporation do?

Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics. The company's core offerings include microarray printing technology, automated microarray manufacturing instruments, and related consumables. Arrayit serves genomic research centers, pharmaceutical companies, academic institutions, and other organizations involved in life science research and diagnostics, providing tools for gene expression analysis, genotyping, and protein profiling.

What do analysts say about ARYC stock?

There is currently no available analyst coverage or consensus on Arrayit Corporation (ARYC) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in ARYC. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to limited financial disclosure and trading activity.

What are the main risks for ARYC?

The main risks for Arrayit Corporation include its negative profit margin, small market capitalization, and high beta, indicating high volatility. As an OTC-listed company, ARYC faces additional risks related to limited financial disclosure, low trading volume, and potential for price manipulation. Competition from larger companies with greater resources and regulatory changes in the medical diagnostics industry also pose significant challenges. Investors should carefully consider these risks before investing.